Uncapped: Stories from the Grey Market – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Uncapped: Stories from the Grey Market

krysia

Health & Fitness

Frequency: 1 episode/4d. Total Eps: 65

Uncapped, the podcast that dives deep into the underground world of grey market peptides, research compounds, and the Discord and Telegram communities that operate just outside the lines. Each episode blends real events, from chaotic group buys to vendor takedowns, with educational breakdowns, industry interviews, and sharp commentary from the people who live in this unregulated world. Some stories are dramatic. Some are absurd. All are true, or at least, true enough to make you rethink what’s really going on behind the scenes of your favourite “trusted vendor.”

Read moreCollapse

Site

RSS

Apple

Data updated on 14/07/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://peptide.chat/invite/YPEb27jM
4 shares

https://discord.gg/w5ZnyBfZ8a
1 share
https://discord.gg/dnW7tQFU
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 28%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

The Phoenix Group Buy Scam; Part 1

Monday, April 6, 2026 • Duration 10:03

How “seized shipments” turn into second profits and why the same buyers may pay twiceScams are nothing new in the grey market.

But this one works a little differently.

In this episode, we break down what’s being described as the “Phoenix group buy scam” a pattern where a failed or allegedly failed group buy may not be the end of the story.

Instead, it can become the starting point for something else.

We walk through how these setups typically unfold:

how trust is built inside the communityhow buyers are funnelled into group buyshow delays and shortages are normalisedand how the narrative is already in place before anything goes wrongUsing the Opaline Health & Science case as a real example, Part 1 focuses on the structure, not the outcome.

Because the key question isn’t just what happened.

It’s how the system was built to begin with.

Read moreCollapse

Friendship in the Grey Zone; Useful until you're not

Saturday, March 28, 2026 • Duration 05:25

This episode explores a side of the grey zone that isn’t talked about enough.

Not the peptides. Not the vendors. Not the scams.

But the people.

Inside tight-knit communities, friendship often comes with conditions. You’re valuable while you’re useful. But when that changes, so does the relationship.

From gossip, alt accounts, back stabbing and surveillance… to something more personal, the emotional whiplash of people who feel real, disappear, and then return like nothing happened.

This episode is a reflection on hypocrisy, status, loyalty and the shifting terms of friendship in the grey zone

Read moreCollapse

Just another day in the Grey Zone

Wednesday, March 25, 2026 • Duration 07:24

Scams, impersonators, vendor disputes, disappearing chats, and a collaboration offer I definitely wasn’t expecting.

This episode is a real-time look at what one day in the grey zone actually looks like for me, narrated in my own voice.

Read moreCollapse

Vial vs body; Tirzepatide + vitamin B12

Sunday, March 22, 2026 • Duration 19:55

What really happens when tirzepatide and vitamin B12 are mixed in the same vial?

In this deep dive, we break down the science behind Eli Lilly’s recent warning and preprint, which identified a previously unknown tirzepatide–B12 molecular complex in compounded samples, in some cases making up a significant portion of the vial. The analysis also revealed major potency variation, with some products testing far below their labelled strength.

But the real question isn’t just what was found, it’s what it actually means.

We explore:

how and why molecules interact differently in a shared vial vs the human body

what Lilly’s analytical data proves, and what it doesn’t

why formulation conditions (pH, concentration, solvent) can drive structural change

and how theoretical risks like aggregation and immunogenicity should be interpreted

This episode separates chemical possibility from clinical reality, and explains why understanding where interactions occur is key to understanding whether they matter at all.

Read moreCollapse

Eli Lilly's Tirzepatide and B12 warning;

Friday, March 20, 2026 • Duration 20:43

What their data shows and what it still doesn't explain.

What happens when a blockbuster drug meets a common vitamin?

In this deep dive, we unpack Eli Lilly’s warning about tirzepatide mixed with vitamin B12, and the science behind the controversy.

A newly released preprint shows that when the two are combined, they can form a previously unknown molecular complex, detected in real world samples. Some products were also found to be significantly under strength, raising broader concerns about quality in the secondary market.

But while the chemistry is real, the key question remains unanswered:

does any of this actually matter for patients?

We break down:

what Lilly’s data actually proves

how the molecules interact at a structural level

why lab findings don’t automatically translate to real-world risk

and how this fits into the wider $100B GLP-1 market battle

This isn’t just a story about one drug or one impurity, it’s about the gap between analytical evidence and clinical reality, and what happens when patients are caught in the middle.

Read moreCollapse

The NAD Testing Paradox

Monday, March 16, 2026 • Duration 09:35

Why do some labs report 99%+ purity for NAD, while others refuse to give a purity number at all?

This episode unpacks what is known as the NAD Testing Paradox.

NAD is often analysed using methods designed for peptides, but chemically it behaves very differently. Because NAD naturally breaks down into related molecules like nicotinamide, ADP-ribose, AMP and ADP, purity numbers can sometimes reflect the analytical method used, rather than the actual chemical state of the molecule.

Using real COA examples, this episode explores;

why peptide style testing can be misleading for NAD

how different labs can end up reporting very different numbers

cases where laboratories even disagreed on the identity of a sample

what a properly selective NAD testing method actually looks like

The goal isn’t to criticise labs, but to explain why NAD purity numbers can appear contradictory, and what those results may actually be measuring.

Read moreCollapse

What comes after RUO?

Sunday, March 15, 2026 • Duration 19:24

How Telehealth, US Manufacturing and 503A Ambitions are Rebuilding the Peptide Market

The peptide market may be moving into a new phase.

For years, much of the industry operated through Research Use Only (RUO) websites selling peptides in a legal grey zone. But that model is coming under pressure from payment processors, regulators, and changing mrket expectations.

This episode explores what may be replacing it.

Rather than a simple shift from RUO vendors to legitimate pharmacies, a more complex infrastructure appears to be emerging: telehealth platforms, physician sign-off models, compounding pharmacies, and even underground U.S. manufacturing operations trying to move toward 503A licensing over time.

We break down how clinics created demand for alternative peptide supply, why telehealth has become such an attractive distribution layer, what legitimate sterile compounding actually involves, and why some operators may be using telehealth as a bridge toward a more defensible healthcare structure.

The key point is that this is not a clean transition from grey market to regulated pharmacy.

It is a hybrid phase in which:

some operations are fully licensed pharmacies

some are Telehealth driven prescribing systems

some are clinic facing vendor networks wrapped in physician sign-off

and some may be underground U.S. manufacturers trying to acquire the telehealth layer now and the 503A wrapper later

Demand for peptides hasn’t disappeared.

What’s changing is the infrastructure through which that demand is served, and who manages to control the next version of the market.

Read moreCollapse

The Real Pressure Behind the end of RUO; The Payment Processors

Saturday, March 14, 2026 • Duration 23:08

For years the grey-market peptide ecosystem operated in a strange legal balance. Products were sold under “Research Use Only” labels while being widely discussed in wellness communities, clinics, and online forums. Regulators knew the contradiction existed, but the system continued to function.

So what is actually destabilising the RUO model now?

In this episode we look at a factor that rarely gets discussed: payment processors.

Behind the scenes, vendors report increasing pressure from banks and card networks. High-risk merchant classifications, rolling reserves, frozen balances, and sudden account shutdowns are becoming common. Some companies now struggle not because they can’t produce peptides, but because they can’t reliably get paid for them.

We explore how payment infrastructure is beginning to shape business behaviour across the peptide market. Vendors are experimenting with crypto checkout bridges, limiting sales volumes to avoid scrutiny, or moving toward telehealth and compounding pharmacy partnerships that qualify for healthcare merchant certifications like LegitScript.

From this perspective, the shift happening in the peptide industry may not simply be RUO vendors rebranding as PUO or moving toward compounding pharmacies.

It may be something more fundamental.

The companies that control the rails of money may ultimately decide which peptide business models survive.

Read moreCollapse

From RUO to PUO; How the peptide industry is relabelling the same supply model

Saturday, March 14, 2026 • Duration 19:25

In this episode we unpack the shift from Research Use Only (RUO) peptides to the emerging Physician Use Only (PUO) label.

At first glance, PUO might look like a move toward a more legitimate, physician-driven distribution model. But a closer look suggests something more complex.

PUO is not an FDA regulatory category and does not automatically place peptides inside licensed pharmacy frameworks such as 503A or 503B compounding. Instead, it appears to function primarily as a liability repositioning strategy, allowing vendors to distance themselves from direct human use claims while shifting more responsibility toward physicians and clinics.

We explore how the original RUO label emerged, why that model began to break down, and how some vendors are now rebranding products for “physician use” while still operating outside formal drug approval pathways.

The episode also looks at real examples from companies marketing peptides to clinicians while still including research-use disclaimers , creating a hybrid system where the marketing suggests therapeutic use but the legal framework remains unchanged.

The key takeaway: PUO may change the language around peptides, but it does not necessarily change the underlying regulatory structure.

And while RUO vendors rebrand, a parallel system built around telehealth and compounding pharmacies may be emerging at the same time.

Read moreCollapse

K-Hole Origins; #4; Dear Friend, Where's my Refund

Saturday, March 14, 2026 • Duration 16:22

In this audio version episode of K-Hole Origins: My Road to Grey, I talk about my experience with a vendor known as Cora and how a seemingly normal transaction slowly turned into a lesson in how the grey market actually works.

It started in March 2024. Cora approached me warmly, calling me “dear friend,” reassuring me about shipping and reship policies, and sending an Alibaba payment link for tirzepatide. The first order actually arrived, which gave me confidence to place a second, larger order for several peptides.

But once testing results came back through PTDS, the picture changed. Multiple products, MOTS-C, DSIP and Epitalon, were under dosed. When I asked for a refund, the conversation shifted into what I now recognise as the classic grey-market script: reassurance, batch excuses, replacement offers instead of refunds, and endless procedural delays.

The refund became a negotiation. The amount kept shrinking. I was asked to keep the agreement secret and even asked to delete posts discussing the issue. When the agreed refund still didn’t appear, the process was pushed into complicated Alibaba procedures that never actually resolved anything.

In the end, the only thing that worked was a credit-card chargeback.

What began with hearts, “dear friend,” and friendly messages ended with a defence letter claiming I was unreasonable and spreading rumours.

Read moreCollapse

Uncapped: Stories from the Grey Market – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Uncapped: Stories from the Grey Market – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other1

Substack2

Discord2

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other1

Substack2

Discord2